Ceramide Is Upregulated and Associated With Mortality in Patients With Chronic Heart Failure

Canadian Journal of Cardiology

Volumn 31, Issue 3, 2015, Pages 357-363

  Yu, Jingjia ^a   Pan, Wei ^b   Shi, Ruizheng ^b   Yang, Tianlun ^b   Li, Yuanjian ^b   Yu, Guolong ^b   Bai, Yongping ^b   Schuchman, Edward H ^c   He, Xingxuan ^c   Zhang, Guogang ^b  

^a Central South University   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE; BIOLOGICAL MARKER;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; RISK ASSESSMENT; SURVIVAL; UPREGULATION; AGED; BLOOD; CASE CONTROL STUDY; CHRONIC DISEASE; KAPLAN MEIER METHOD; MIDDLE AGED; PROGNOSIS; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CERAMIDES; CHRONIC DISEASE; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 84923914371     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2014.12.007     Document Type: Article

References (31)

1. Hannun Y.A., Obeid L.M. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 2008, 9:139-150.
2. Hannun Y.A., Obeid L.M. Many ceramides. JBiol Chem 2011, 286:27855-27862.
3. Li X., Becker K.A., Zhang Y. Ceramide in redox signaling and cardiovascular diseases. Cell Physiol Biochem 2010, 26:41-48.
4. Smith E.L., Schuchman E.H. The unexpected role of acid sphingomyelinase in cell death and the pathophysiology of common diseases. FASEB J 2008, 22:3419-3431.
5. Gajarsa J.J., Kloner R.A. Left ventricular remodeling in the post-infarction heart: a review of cellular, molecular mechanisms, and therapeutic modalities. Heart Fail Rev 2011, 16:13-21.
6. Kalogeropoulos A., Georgiopoulou V., Psaty B.M., et al. Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study. JAm Coll Cardiol 2010, 55:2129-2137.
7. Arbustini E., Brega A., Narula J. Ultrastructural definition of apoptosis in heart failure. Heart Fail Rev 2008, 13:121-135.
8. Consoli C., Gatta L., Iellamo F., et al. Severity of left ventricular dysfunction in heart failure patients affects the degree of serum-induced cardiomyocyte apoptosis. Importance of inflammatory response and metabolism. Int J Cardiol 2013, 167:2859-2866.
9. Doehner W., Bunck A.C., Rauchhaus M., et al. Secretory sphingomyelinase is upregulated in chronic heart failure: a second messenger system of immune activation relates to body composition, muscular functional capacity, and peripheral blood flow. Eur Heart J 2007, 28:821-828.
10. Dickstein K., Cohen-Solal A., Filippatos G., et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008, 29:2388-2442.
11. Liebisch G., Drobnik W., Reil M., et al. Quantitative measurement of different ceramide species from crude cellular extracts by electrospray ionization tandem mass spectrometry (ESI-MS/MS). JLipid Res 1999, 40:1539-1546.
12. Yoo H.H., Son J., Kim D.H. Liquid chromatography-tandem mass spectrometric determination of ceramides and related lipid species in cellular extracts. JChromatogr B Analyt Technol Biomed Life Sci 2006, 843:327-333.
13. Bantis L.E., Nakas C.T., Reiser B. Construction of confidence regions in the ROC space after the estimation of the optimal Youden index-based cut-off point. Biometrics 2014, 70:212-223.
14. DeLong E.R., DeLong D.M., Clarke-Pearson D.L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988, 44:837-845.
15. Pencina M.J., D'Agostino R.B., Steyerberg E.W. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011, 30:11-21.
16. Pencina M.J., Sr D'Agostino RB., D'Agostino R.B., Vasan R.S. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008, 27:157-172. [discussion: 207-12].
17. Chokshi A., Drosatos K., Cheema F.H., et al. Ventricular assist device implantation corrects myocardial lipotoxicity, reverses insulin resistance, and normalizes cardiac metabolism in patients with advanced heart failure. Circulation 2012, 125:2844-2853.
18. Chiu H.C., Kovacs A., Ford D.A., et al. Anovel mouse model of lipotoxic cardiomyopathy. JClin Invest 2001, 107:813-822.
19. Jenkins R.W., Canals D., Idkowiak-Baldys J., et al. Regulated secretion of acid sphingomyelinase: implications for selectivity of ceramide formation. JBiol Chem 2010, 285:35706-35718.
20. Braunwald E. Biomarkers in heart failure. NEngl J Med 2008, 358:2148-2159.
21. Zeidan Y.H., Hannun Y.A. The acid sphingomyelinase/ceramide pathway: biomedical significance and mechanisms of regulation. Curr Mol Med 2010, 10:454-466.
22. Miettinen K.H., Lassus J., Harjola V.P., et al. Prognostic role of pro- and anti-inflammatory cytokines and their polymorphisms in acute decompensated heart failure. Eur J Heart Fail 2008, 10:396-403.
23. Jessup M., Abraham W.T., Casey D.E., et al. 2009 Focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009, 119:1977-2016.
24. Clerico A., Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clin Chem 2004, 50:33-50.
25. Worster A., Balion C.M., Hill S.A., et al. Diagnostic accuracy of BNP and NT-proBNP in patients presenting to acute care settings with dyspnea: a systematic review. Clin Biochem 2008, 41:250-259.
26. Kistorp C., Faber J., Galatius S., et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005, 112:1756-1762.
27. Gardner R.S., Ozalp F., Murday A.J., Robb S.D., McDonagh T.A. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 2003, 24:1735-1743.
28. Maisel W.H., Stevenson L.W. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003, 91:2D-8D.
29. Anand I., McMurray J.J., Whitmore J., et al. Anemia and its relationship to clinical outcome in heart failure. Circulation 2004, 110:149-154.
30. Gaggin H.K., Januzzi J.L. What is the role of serial high-sensitivity troponin measurements in chronic heart failure?. Clin Chem 2012, 58:1079-1081.
31. Jankowska E.A., Rozentryt P., Witkowska A., et al. Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010, 31:1872-1880.